Chapter 30. Sickle Cell Disease

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director2,3,
  2. Jeff Ginsberg MD, FRCPC Professor4,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor5,6,
  4. Ralph M. Meyer MD, FRCPC Director Professor7,8 and
  5. Richard Lottenberg MD, FACP Professor9
  1. Richard Lottenberg MD, FACP Professor9 and
  2. Sally C. Davies MB, FRCP, FRCPath Faculty of Medicine1

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch30

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Lottenberg, R. and Davies, S. C. (2009) Sickle Cell Disease, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch30

Editor Information

  1. 2

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 3

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 4

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 5

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 6

    McMaster University, Hamilton, Canada

  6. 7

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 8

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 9

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. 1

    Imperial College at Central Middlesex Hospital, London, UK

  2. 9

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857

SEARCH

Keywords:

  • Sickle cell disease (SCD);
  • MEDLINE, the Cochrane Collaboration Cystic Fibrosis and Genetic Disorders Group;
  • Stroke Prevention Trial in Sickle Cell Anemia (STOP);
  • major randomized clinical trials in sickle cell disease;
  • preoperative red blood cell transfusion in SCD;
  • hydroxyurea therapy indications in SCD;
  • hydroxyurea therapy for adult patients with Hb SS and Hb S/β0 thalassemia;
  • SCD and optimal screening strategy for pulmonary hypertension

Summary

This chapter contains sections titled:

  • Background

  • Literature-search strategy and grading the evidence

  • In patients with SCD, what is the appropriate primary stroke prevention strategy?

  • For patients with SCD who have experienced stroke in childhood, what is the duration of maintaining chronic blood transfusion?

  • What are the indications for preoperative red blood cell transfusion in SCD?

  • What are the indications for hydroxyurea therapy in SCD?

  • In patients with SCD what is the optimal screening strategy for pulmonary hypertension?

  • Acknowledgments

  • References